Skip to main content
Top
Published in: Supportive Care in Cancer 10/2018

01-10-2018 | Original Article

The timeliness of patients reporting the side effects of chemotherapy

Authors: Ian Olver, Mariko Carey, Allison Boyes, Alix Hall, Natasha Noble, Jamie Bryant, Justin Walsh, Rob Sanson-Fisher

Published in: Supportive Care in Cancer | Issue 10/2018

Login to get access

Abstract

Purpose

To explore the actions cancer patients reported they would take in response to a range of common side effects of chemotherapy and whether these were considered appropriate based on current guidelines and evidence; and to explore the sociodemographic and cancer-related variables associated with patients selecting the appropriate action (immediate medical attention or reporting) for two potentially life-threatening side effects: fever, and unusual bleeding and bruising.

Methods

Four hundred thirty-six medical oncology and haematology patients receiving chemotherapy completed two surveys to provide demographic, disease and treatment characteristics, and details on how they would respond if they experienced a range of specified side effects of chemotherapy (for example, nausea and vomiting, fatigue, and skin rash or nail changes). The proportion of patients reporting the appropriate action for each side effect was calculated. Multiple logistic regressions examined the patient demographic and cancer characteristics associated with selecting the appropriate action (seeking immediate medical attention) for two potentially life-threatening side effects of chemotherapy: high fever of 38 °C or more, and unusual bleeding or bruising.

Results

Two thirds of patients indicated that they would seek immediate medical attention for high fever (67%), but only 41% would seek immediate attention for bleeding or bruising. Cancer type and time since diagnosis were significantly associated with patients indicating that they would seek immediate medical attention for high fever; while time since diagnosis was the only variable significantly associated with patients reporting that they would seek immediate medical attention for unusual bleeding or bruising. For chronic side effects, like skin rash or nail changes, and tingling or numbness, which usually do not require urgent reporting, only between 12 and 16% would report them immediately. A significant proportion of patients reported that they would “do nothing” about fatigue or tiredness (24%). By comparison, less than 10% patients reported that they would do nothing for the other side effects investigated.

Conclusions

Tools need to be created so that patients better understand the side effects after being treated with chemotherapy and what action they should take.
Literature
1.
go back to reference Wagland R, Richardson A, Ewings S, Armes J, Lennan E, Hankins M, Griffiths P (2016) Prevalence of cancer chemotherapy-related problems, their relation to health-related quality of life and associated supportive care: a cross-sectional survey. Support Care Cancer 24:4901–4911CrossRefPubMed Wagland R, Richardson A, Ewings S, Armes J, Lennan E, Hankins M, Griffiths P (2016) Prevalence of cancer chemotherapy-related problems, their relation to health-related quality of life and associated supportive care: a cross-sectional survey. Support Care Cancer 24:4901–4911CrossRefPubMed
2.
go back to reference Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Ruhlmann CH, Walsh D, Warr D, van der Wetering M (2016) MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27(Suppl 5):v119–v133CrossRefPubMed Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Ruhlmann CH, Walsh D, Warr D, van der Wetering M (2016) MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27(Suppl 5):v119–v133CrossRefPubMed
3.
go back to reference Llopis-Salvia P, Sarrio-Montes G, Garcia-Liopis P, Bargues-Ruiz A (2010) Chemotherapy dose intensity due to adverse drug reactions in the oncology outpatient setting. J Oncol Pharm Pract 16:256–261CrossRefPubMed Llopis-Salvia P, Sarrio-Montes G, Garcia-Liopis P, Bargues-Ruiz A (2010) Chemotherapy dose intensity due to adverse drug reactions in the oncology outpatient setting. J Oncol Pharm Pract 16:256–261CrossRefPubMed
4.
go back to reference Vandyk AD, Harrison MB, Macartney G, Ross-White A, Stacey D (2012) Emergency department visits for symptoms experienced by oncology patients: a systematic review. Support Care Cancer 20:1589–1599CrossRefPubMed Vandyk AD, Harrison MB, Macartney G, Ross-White A, Stacey D (2012) Emergency department visits for symptoms experienced by oncology patients: a systematic review. Support Care Cancer 20:1589–1599CrossRefPubMed
5.
go back to reference McKenzie H, Hayes L, White K, Cox K, Fethney J, Boughton M, Dunn J (2011) Chemotherapy outpatients’ unplanned presentations to hospital: a retrospective study. Support Care Cancer 19:963–969CrossRefPubMed McKenzie H, Hayes L, White K, Cox K, Fethney J, Boughton M, Dunn J (2011) Chemotherapy outpatients’ unplanned presentations to hospital: a retrospective study. Support Care Cancer 19:963–969CrossRefPubMed
6.
go back to reference Binkley JM, Harris SR, Levangie PK, Pearal M, Guglielmino J, Kraus V, Rowden D (2012) Patient perspectives on breast cancer treatment side effects and the prospective surveillance model for physical rehabilitation for women with breast cancer. Cancer 118:2207–2216CrossRefPubMed Binkley JM, Harris SR, Levangie PK, Pearal M, Guglielmino J, Kraus V, Rowden D (2012) Patient perspectives on breast cancer treatment side effects and the prospective surveillance model for physical rehabilitation for women with breast cancer. Cancer 118:2207–2216CrossRefPubMed
7.
go back to reference Kearney N, Kidd L, Miller M, Sage M, Khorrami J, McGee M, Cassidy J, Niven K, Gray P (2006) Utilising handheld computers to monitor and support patients receiving chemotherapy: results of a UK-based feasibility study. Support Care Cancer 14:742–752CrossRefPubMed Kearney N, Kidd L, Miller M, Sage M, Khorrami J, McGee M, Cassidy J, Niven K, Gray P (2006) Utilising handheld computers to monitor and support patients receiving chemotherapy: results of a UK-based feasibility study. Support Care Cancer 14:742–752CrossRefPubMed
8.
go back to reference Valenti RB (2014) Chemotherapy education for patients with cancer: a literature review. Clin J Oncol Nurs 18:637–640CrossRefPubMed Valenti RB (2014) Chemotherapy education for patients with cancer: a literature review. Clin J Oncol Nurs 18:637–640CrossRefPubMed
9.
go back to reference Homsi J, Walsh D, Rivera N, Rybicki LA, Nelson KA, Legrand SB, Davis M, Naughton M, Gvozdjan D, Pham H (2006) Symptom evaluation in palliative medicine: patient report vs systematic assessment. Support Care Cancer 14:444–453CrossRefPubMed Homsi J, Walsh D, Rivera N, Rybicki LA, Nelson KA, Legrand SB, Davis M, Naughton M, Gvozdjan D, Pham H (2006) Symptom evaluation in palliative medicine: patient report vs systematic assessment. Support Care Cancer 14:444–453CrossRefPubMed
10.
go back to reference Coolbrandt A, Van den Heede K, Vanhove E, De Bom A, Milisen K, Wildiers H (2011) Immediate versus delayed self-reporting of symptoms and side effects during chemotherapy: does timing matter? Eur J Oncol Nurs 15:130–136CrossRefPubMed Coolbrandt A, Van den Heede K, Vanhove E, De Bom A, Milisen K, Wildiers H (2011) Immediate versus delayed self-reporting of symptoms and side effects during chemotherapy: does timing matter? Eur J Oncol Nurs 15:130–136CrossRefPubMed
11.
go back to reference Olver IN, Matthews J, Bishop JF, Smith R (1994) The roles of patient and observer assessments in anti-emetic trials. Eur J Cancer 1994(30A):1223–1227CrossRef Olver IN, Matthews J, Bishop JF, Smith R (1994) The roles of patient and observer assessments in anti-emetic trials. Eur J Cancer 1994(30A):1223–1227CrossRef
12.
go back to reference Basch E, Artz D, Dulko D, Scher K, Sabbatini P, Hensley M, Mitra N, Speakman J, McCabe M, Schrag D (2005) Patient online self-reporting of toxicity symptoms during chemotherapy. J Clin Oncol 2:3552–3561CrossRef Basch E, Artz D, Dulko D, Scher K, Sabbatini P, Hensley M, Mitra N, Speakman J, McCabe M, Schrag D (2005) Patient online self-reporting of toxicity symptoms during chemotherapy. J Clin Oncol 2:3552–3561CrossRef
13.
go back to reference Olsen H, Klemetsrud T, Stokke HP, Tretli S, Westheim A (1999) Adverse drug reactions in current antihypertensive therapy: a general practice survey of 2586 patients in Norway. Blood Press 8:94–101CrossRefPubMed Olsen H, Klemetsrud T, Stokke HP, Tretli S, Westheim A (1999) Adverse drug reactions in current antihypertensive therapy: a general practice survey of 2586 patients in Norway. Blood Press 8:94–101CrossRefPubMed
14.
go back to reference Bergman MM, Byers T, Freedman DS, Mokdad A (1998) Validity of self-reported diagnoses leading to hospitalization: a comparison of self-reports with hospital records in a prospective study of American adults. Am J Epidemiol 147:969–977CrossRef Bergman MM, Byers T, Freedman DS, Mokdad A (1998) Validity of self-reported diagnoses leading to hospitalization: a comparison of self-reports with hospital records in a prospective study of American adults. Am J Epidemiol 147:969–977CrossRef
18.
go back to reference Adams RJ, Appleton SL, Hill CL, Dodd M, Findlay C, Wilson DH (2009) Risks associated with low functional health literacy in an Australian population. Me J Aust 191:530–534 Adams RJ, Appleton SL, Hill CL, Dodd M, Findlay C, Wilson DH (2009) Risks associated with low functional health literacy in an Australian population. Me J Aust 191:530–534
19.
go back to reference Galdas PM, Cheater F, Marshall P (2005) Men and health seeking behaviour: literature review. J Adv Nurs 49:616–623CrossRefPubMed Galdas PM, Cheater F, Marshall P (2005) Men and health seeking behaviour: literature review. J Adv Nurs 49:616–623CrossRefPubMed
20.
go back to reference Jung HP, Baerveldt C, Olesen F, Grol R, Wensing M (2003) Patient characteristics as predictors of primary health care preferences: a systematic literature analysis. Health Expect 6:160–181CrossRefPubMedPubMedCentral Jung HP, Baerveldt C, Olesen F, Grol R, Wensing M (2003) Patient characteristics as predictors of primary health care preferences: a systematic literature analysis. Health Expect 6:160–181CrossRefPubMedPubMedCentral
23.
go back to reference Kuter DJ (2015) Managing thrombocytopenia associated with cancer chemotherapy. Oncology (Williston Park) 29:282–294 Kuter DJ (2015) Managing thrombocytopenia associated with cancer chemotherapy. Oncology (Williston Park) 29:282–294
24.
go back to reference Hershman D, Calhoun E, Zapert K, Wade S, Malin J, Barron R (2008) Patients’ perceptions of physician-patient discussions and adverse events with cancer therapy. Arch Drug Info 1:70–78CrossRef Hershman D, Calhoun E, Zapert K, Wade S, Malin J, Barron R (2008) Patients’ perceptions of physician-patient discussions and adverse events with cancer therapy. Arch Drug Info 1:70–78CrossRef
25.
go back to reference Whitford HS, Olver IN (2012) When expectations predict experience: the influence of psychological factors on chemotherapy toxicities. J Pain Symptom Manag 43:1036–1050CrossRef Whitford HS, Olver IN (2012) When expectations predict experience: the influence of psychological factors on chemotherapy toxicities. J Pain Symptom Manag 43:1036–1050CrossRef
26.
go back to reference Valenti RB (2014) Chemotherapy education with patients with cancer: a literature review. Clin J Cancer Nurs 18:637–640 Valenti RB (2014) Chemotherapy education with patients with cancer: a literature review. Clin J Cancer Nurs 18:637–640
28.
go back to reference Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, Howe HL, Thun M (2006) Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 56:168–183CrossRefPubMed Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, Howe HL, Thun M (2006) Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 56:168–183CrossRefPubMed
29.
go back to reference Olver IN, Eliott JA, Long L, McKinnon M, Rumsby G (2012) The impact of receiving treatment for cancer at a large metropolitan teaching hospital as recorded by patients using unstructured journals. J Cancer Educ 27:625–630CrossRefPubMed Olver IN, Eliott JA, Long L, McKinnon M, Rumsby G (2012) The impact of receiving treatment for cancer at a large metropolitan teaching hospital as recorded by patients using unstructured journals. J Cancer Educ 27:625–630CrossRefPubMed
30.
go back to reference Lamnguis-Eklöf A, Crafoord M-T, Christiansen M, Fjell M, Sundberg K (2017) Effects of an interactive mHealth innovation for early detection of patient-reported symptom distress with focus on participatory care: randomized, controlled trials in patients with prostate and breast cancer. BMC Cancer 17:466. https://doi.org/10.1186/s12885-017-3450-y CrossRef Lamnguis-Eklöf A, Crafoord M-T, Christiansen M, Fjell M, Sundberg K (2017) Effects of an interactive mHealth innovation for early detection of patient-reported symptom distress with focus on participatory care: randomized, controlled trials in patients with prostate and breast cancer. BMC Cancer 17:466. https://​doi.​org/​10.​1186/​s12885-017-3450-y CrossRef
Metadata
Title
The timeliness of patients reporting the side effects of chemotherapy
Authors
Ian Olver
Mariko Carey
Allison Boyes
Alix Hall
Natasha Noble
Jamie Bryant
Justin Walsh
Rob Sanson-Fisher
Publication date
01-10-2018
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 10/2018
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-018-4225-y

Other articles of this Issue 10/2018

Supportive Care in Cancer 10/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine